Q-omics provides the consensus-scored ELOA2 profile across patient tissues and cancer cell-line models. ELOA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ELOA2 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, ELOA2 RNA expression shows 14,714 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where ELOA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOA2 survival associations across molecular data types. ELOA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOA2 RNA expression–survival associations across cancer types. High ELOA2 expression shows unfavorable associations in UVM, UCEC, ACC, READ, KIRC and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ELOA2 RNA expression.
This table summarizes ELOA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOA2 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUSC, KICH, BRCA and UCEC. The BLCA box plot shows higher ELOA2 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p < 0.001).
This table shows molecular features associated with ELOA2 in patient tissues and cancer cell lines. In patient samples, ELOA2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
